Cardiovascular benefits of PCSK9 inhibition

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1010867

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

PCSK9 is an inhibitor of the receptor that is responsible for removing LDL (the bad cholesterol) from the circulation. We will study the molecular mechanisms that inhibit PCSK9 at the protein level. This study is needed to understand if drugs that inhibit PCSK9 will diminish the risk of developing heart disease in patients who do not respond well to existing treatments, for example those who already had a cardiovascular event or those with familial hypercholesterolemia.

Funded Activity Details

Start Date: 01-01-2011

End Date: 01-01-2013

Funding Scheme: Project Grants

Funding Amount: $518,386.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Receptors and Membrane Biology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

atherosclerosis | cardiovascular disease | lipoprotein metabolism | myocardial infarction | protein localisation | receptor regulation

Related Links